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Can we improve melanoma 
detection methods?
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The incidence and mortality of melanoma 
have been steadily increasing over the last 
decade, leading this tumor to be considered 
a public health issue.
In 2016, the estimated number of new 
melanoma cases in the USA was 76,380, 
with an incidence rate of 23.6 per 100,000 
inhabitants [1].
In the European Union, melanoma inci-
dence accounts for 9 per 100,000 people per 
year, with higher rates in fair-skin popula-
tions; however, the real incidence is thought 
to be higher because of underestimation of 
the most superficial and indolent cases [1].
Melanoma generally affects younger 
patients more than other tumors; in fact, 
it represents the third most frequent tumor 
before 49 years of age [1].
Concerning mortality, melanoma 
accounts for up to 65% of the deaths 
for skin cancers, while representing only 
3–5% of all skin tumors, with a rate of 2.3 
per 100,000 inhabitants per year [2].
The rising rates in melanoma detec-
tion seem to be only partially due to the 
development and wider use of noninvasive 
diagnostic tools. In fact, while this could 
justify the higher incidences of indolent 
and noninvasive melanomas, it does not 
explain the increasing mortality rates.
Several factors may contribute in defin-
ing the prognostic profile of melanoma 
patients. Among these, Breslow’s thickness 
plays a major role. In fact, in thin melano-
mas (≤1.0 mm), a 90% 5-year survival has 
been reported; survival rates dramatically 
decrease in visceral metastatic cases, with 
a 1-year survival as low as 33% [3].
Even though new oncogenic and immu-
nological target therapies for metastatic 
cases have been increasing survival rates, 
early diagnosis and excision with proper 
margins remain the best therapeutic 
option. Optimal diagnostic methods that 
might increase the diagnostic accuracy for 
melanoma are crucial.
Histopathological examination still 
represents a necessary stage to confirm 
melanoma diagnosis. Nevertheless, non-
invasive diagnostic methods have, in 
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“The incidence and mortality 
of melanoma have been 
steadily increasing over the 
last decade, leading this 
tumor to be considered a 
public health issue.”
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the past decades, significantly decreased the 
number of unnecessary biopsies and excisions, 
and increased the sensibility and specificity in 
diagnosing melanocytic lesions. Undoubtedly, 
dermoscopy and reflectance confocal micro-
scopy (RCM) played a leading role in the field 
of diagnostic imaging techniques.
The role of dermoscopy in improving mela-
noma detection was clearly demonstrated by a 
recent meta-analysis, in which 90% sensibility 
was reported, compared with 74% from the 
naked-eye examination [4]. The ease of use and 
the development of new handheld and port-
able instruments have favored the worldwide 
diffusion of this technique.
Furthermore, the performance of dermo scopy 
varies consistently according to the expertise 
of users. In fact, it has been estimated that, 
in nonspecialized clinical settings, a number 
of 29.4 nevi are biopsied for every melanoma 
detected; however in experienced hands, the 
number needed to excise decreases to 8.7 [5].
In 2003, an online consensus meeting 
answered the need for better standardization 
of dermoscopic terminology, defining the let-
ters of the dermoscopic alphabet [6]. A two-step 
procedure was proposed, the first differentiating 
melanocytic from nonmelanocytic lesions, the 
second differentiating melanoma from benign 
melanocytic lesions through four different algo-
rithms: modified pattern analysis [7]; ABCD 
rule of dermoscopy [8]; Menzies method [9]; and 
seven-point checklist [10].
Sensitivity levels >90% in diagnosing mela-
noma were calculated for the first step while, 
for the second, the pattern analysis showed the 
best performance, with sensitivity and specificity 
levels >80% [6].
Some limitations of this procedure are repre-
sented by fully regressive and amelanotic lesions, 
lesions located on the face and patients with 
multiple atypical nevi.
In fully regressive and amelanotic lesions, 
the evaluation of the first step may be very 
challenging because of the featureless nature 
of amelanotic lesions and the similarity in the 
dermoscopic appearance of regression between 
melanocytic and nonmelanocytic lesions. Even 
though some dermoscopic differences and algo-
rithms have been described, in these cases a 
biopsy remains mandatory [11,12].
The location on the face may also affect the 
evaluation of the initial step. In 2000, specific 
dermoscopic criteria for the diagnosis of lentigo 
maligna were described along with a progres-
sion model toward multiple steps from in situ 
to invasive lentigo maligna [13]. Nevertheless, 
because of the anatomic structure of skin of the 
face, solar lentigo and pigmented actinic kera-
tosis may be dermoscopically indistinguishable 
from lentigo maligna. In such cases, a biopsy 
and/or the use of confocal microscopy is strongly 
recommended [14].
Finally, in patients with multiple atypical 
nevi, the second step of the two-step analysis 
may overestimate the number of unnecessary 
surgical excisions. In such cases, the digital 
monitoring of selected skin lesions and the 
comparative approach has shown to significantly 
decrease the number of unnecessary excisions, 
while increasing the probability to diagnose a 
melanoma. In particular, a short (3-month) 
follow-up should be performed in these patients, 
after the first visit, in order to re-evaluate the 
patient and to catch even little modifications in 
the monitored lesions [15].
Recently, new applications of dermoscopy 
have been also explored; in particular, a correla-
tion between certain dermoscopic criteria and 
the mutational status of the BRAF gene were 
demonstrated. Bombonato et al. [16] showed 
that the presence of ulceration and irregular 
peripheral streaks was positively associated with 
a BRAF mutated state, while dotted vessels were 
predictors of wild-type melanomas.
RCM is an add-on tool for noninvasive diag-
nosis of skin tumors, which provides a horizontal 
visualization of the skin at a nearly histological 
resolution. The use of RCM in the clinical prac-
tice has allowed to narrow the grey zone of doubt-
ful clinical and dermoscopic lesions, and to save 
a larger number of benign lesions from excision.
We recently reviewed our 3-year experience 
using RCM as a tertiary referral center, and 
calculated that the number needed to treat for 
melanoma is 1:2.4 [17].
Since the use of RCM is more time consum-
ing than dermoscopy and is not feasible in some 
body sites, such as acral skin, there is a need 
to select the lesions to examine with this tech-
nique. Interestingly, the best indications for 
RCM use in clinical practice are represented by 
lesions located on the head and neck, damaged 
by chronic sun exposure and typified through 
dermoscopy by regression [17].
Focusing on melanocytic lesions, confocal 
microscopy showed high levels of accuracy in 
differentiating melanoma from nevi. In 2005, 
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Pellacani et al. developed a diagnostic algorithm 
for melanoma diagnosis with 97.3% sensitivity 
and 72.3% specificity [18].
In 2009, Segura et al. defined a two-step 
approach for the confocal diagnosis of skin 
tumors, borrowed from the dermoscopic two-
step analysis. For the first step, the following 
criteria were found to be associated with melano-
cytic lesions: cobblestone pattern of epidermal 
layers, pagetoid spread, mesh appearance of the 
dermoepidermal junction and the presence of 
dermal nests. In the second step, the presence of 
roundish suprabasal cells and atypical nucleated 
cells in the dermis was associated with mela-
noma, and the presence of edged papillae and 
typical basal cells was associated with nevi [19].
Even combining clinical, dermoscopic and 
RCM evaluations, the diagnosis of certain types 
of melanoma is still challenging. In particular, the 
definition of confocal criteria for in situ melanoma 
is still lacking, except for lentigo maligna.
Finally, convolutional neural networks 
(CNNs) have been recently explored to clas-
sify skin lesions using a single CNN [20]. In 
this study, the authors tested its performance 
against 21 board-certified dermatologists on 
biopsy-proven clinical images with two critical 
binary classifications: keratinocyte carcinomas 
versus benign seborrheic keratosis; and melano-
mas versus nevi. Notably, the CNN achieved 
an excellent performance across both tasks, 
demonstrating that an artificial intelligence is 
capable to classify skin cancer with a level of 
competence similar to dermatologists. Although 
these data look promising and open new fron-
tiers on automated diagnosis, as clinicians we 
should always take into account that diagnosis 
of melanoma is a complex process that involves 
patient’s data, lesion history, familial history and 
clinical overview that are not included in a static 
dermoscopic image but are rather part of the 
face-to-face visit.
In conclusion, several new techniques have 
been developing, which allow for an increase in 
the level of accuracy in diagnosing melanoma. 
In the near future, we envision the develop-
ment of handy and low-cost imaging tools com-
bined with software that might help the clini-
cians in the detection of difficult-to-diagnose 
melanomas.
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